CANDESARTAN CILEXETIL TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
18-03-2022
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CANDESARTAN CILEXETIL
Fáanlegur frá:
ALEMBIC PHARMACEUTICALS LIMITED
ATC númer:
C09CA06
INN (Alþjóðlegt nafn):
CANDESARTAN
Skammtar:
16MG
Lyfjaform:
TABLET
Samsetning:
CANDESARTAN CILEXETIL 16MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
30/100/1000
Gerð lyfseðils:
Prescription
Lækningarsvæði:
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Vörulýsing:
Active ingredient group (AIG) number: 0135220003; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2014-04-25
Vara einkenni
______________________________________________________________________________
_Candesartan Cilexetil Product Monograph_
_ Page 1 of 39_
PRODUCT MONOGRAPH
PR
CANDESARTAN CILEXETIL
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
MANUFACTURED BY:
Alembic Pharmaceuticals Limited, DATE OF PREPARATION:
Alembic Road, Vadodara 390003,
March 18, 2022
Gujarat, India.
IMPORTED AND DISTRIBUTED BY:
Alembic Pharmaceuticals Canada Ltd.
225 Gibraltar Road, Unit 5
Vaughan, Ontario
L4H 4P9, Canada
Submission
Control Numbers: 257724
______________________________________________________________________________
_Candesartan Cilexetil Product Monograph_
_ Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................3
SUMMARY PRODUCT
INFORMATION...........................................................................3
INDICATIONS AND CLINICAL
USE.................................................................................3
CONTRAINDICATIONS......................................................................................................4
WARNINGS AND PRECAUTIONS
....................................................................................5
ADVERSE
REACTIONS.......................................................................................................9
DRUG
INTERACTIONS.....................................................................................................15
DOSAGE AND ADMINISTRATION
................................................................................19
OVERDOSAGE...................................................................................................................22
ACTION AND CLINICAL
PHARMACOLOGY...............................................................22
STORAGE AND
STABILITY.............................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................
Lestu allt skjalið
